The overall objective is to demonstrate preliminary efficacy of APX005M-carboplatin-PLD and
APX005M-radiotherapy-carboplatin-PLD combinations as treatment for relapsed BRCAwt ovarian
cancer patients, where platinum combination therapy is an option.
Phase:
Phase 2
Details
Lead Sponsor:
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators:
Belgian Gynaecological Oncology Group GSO Global Clinical Research BV Swiss Go Trial Group The Central and Eastern European Gynecologic Oncology Group